Sotorasib + Panitumumab Beneficial for Chemorefractory Metastatic CRC
Reduced hazard ratio seen for disease progression or death with sotorasib-panitumumab versus standard care
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.